Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 993Neoplasms 852Carcinoma, Non-Small-Cell Lung 845Prostatic Neoplasms 528Neoplasm Metastasis 501Leukemia, Myeloid, Acute 489Melanoma 456Colorectal Neoplasms 447Multiple Myeloma 441Lung Neoplasms 422Pancreatic Neoplasms 353Recurrence 350Lymphoma 350Ovarian Neoplasms 341Lymphoma, Non-Hodgkin 329Leukemia 324Leukemia, Lymphocytic, Chronic, B-Cell 302Precursor Cell Lymphoblastic Leukemia-Lymphoma 271Carcinoma, Renal Cell 256Head and Neck Neoplasms 246Brain Neoplasms 245Carcinoma, Hepatocellular 234Glioblastoma 232Squamous Cell Carcinoma of Head and Neck 231Myelodysplastic Syndromes 231Lymphoma, Large B-Cell, Diffuse 228Lymphoma, Follicular 219Colonic Neoplasms 191Stomach Neoplasms 182Rectal Neoplasms 175

Interventions

tazemetostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Interventional × Hepatic Impairment × Clear all
NCT04241835 2026-04-16

A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function

Ipsen

Phase 1 Terminated
18 enrolled
Other solid neoplasm

Hepatic Impairment

Data powered by HemOnc (CC BY 4.0) Colophon âš¡